论文部分内容阅读
腺苷酸活化蛋白激酶(AMPK)是调控能量代谢的重要激酶,在维持机体能量代谢平衡中发挥重要作用。AMPK干扰肿瘤细胞的独特能量代谢方式,广泛影响肿瘤的发生、生长、转移。最近研究表明,活化的AMPK可以抑制哺乳动物雷帕霉素靶蛋白(m TOR)途径的异常活化,同时可通过乙酰辅酶A羧化酶(ACC)磷酸化促进脂肪代谢并诱导细胞周期停滞及细胞凋亡。因此,AMPK有望成为肿瘤治疗的新靶点。本文对AMPK激活剂在抗肿瘤领域中的研究进展进行综述,旨在为AMPK激活剂类抗肿瘤药物的研发提供参考。
Adenylate-activated protein kinase (AMPK) is an important kinase that regulates energy metabolism and plays an important role in maintaining energy balance in the body. AMPK interferes with the unique energy metabolism of tumor cells and widely affects tumorigenesis, growth and metastasis. Recent studies have shown that activated AMPK can inhibit the abnormal activation of mammalian target of rapamycin (m TOR) pathway, while promoting lipid metabolism through acetyl-CoA carboxylase (ACC) phosphorylation and induce cell cycle arrest and cells Apoptosis. Therefore, AMPK is expected to become a new target for cancer treatment. This review summarizes the progress of AMPK activators in the field of antitumor and aims to provide a reference for the development of AMPK activator antitumor drugs.